Scholars Central

Case reportPublished 2019

Reduction of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Treated by Nivolumab

Authors: Cai Z, Tian X, Dong L

Journal of Clinical Case Reports

Volume 9 · Issue 4 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Nivolumab is an immune checkpoint inhibitor used to treat various advanced malignancies including metastatic non-small cell lung cancer. The side effects of immunotest inhibitors are different from traditional cytotoxic chemotherapy and pericardial effusion is one of the adverse effects of immunotherapy. However, here we present a 59-year-old male with advanced non-small cell lung cancer (NSCLC) treated with nivolumab who successfully managed reduction of pericardial effusion in patients treated by Nivolumab after 11 cycles. During the treatment, he underwent only one pericardial puncture and drainage of pericardial effusion.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Case Reports.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Case Reports
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Cai Z”
  • BylineArticles whose byline prints “Tian X”
  • BylineArticles whose byline prints “Dong L”